Acute Myocardial Infarction Market Report 2026

Acute Myocardial Infarction Market Overview

• Acute Myocardial Infarction market size has reached to $1.56 billion in 2025 • Expected to grow to $2.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: Rising Hypertension Cases Fueling The Growth Of The Market Due To Increasing Risk Of Heart Attacks • Market Trend: Regulatory Approvals Drive Innovation In Acute Myocardial Infarction Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Acute Myocardial Infarction Market?

Acute myocardial infarction (MI), commonly referred to as a heart attack, is characterized by the death of heart muscle tissue due to a sudden decrease or cessation of blood flow in one or more coronary arteries. This condition leads to myocardial necrosis, primarily caused by the rupture of atherosclerotic plaques, which results in acute obstruction of blood flow. The main types of myocardial infarction are ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). ST-elevation myocardial infarction (STEMI) refers to a severe type of heart attack caused by a complete blockage of a coronary artery, leading to a significant reduction in blood flow to the heart muscle. The treatment options for acute myocardial infarction include thrombolytic therapy, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and medications. Diagnosis is carried out using electrocardiograms (ECG), cardiac biomarkers, echocardiography, coronary angiography, magnetic resonance imaging (MRI), and computed tomography (CT) scans. The available routes of administration are oral, intravenous (IV), subcutaneous, transdermal, and sublingual. The primary end users include hospitals and clinics, ambulatory surgical centers, specialty cardiac centers, and research institutes.

What Is The Acute Myocardial Infarction Market Growth Forecast?

The acute myocardial infarction market size is expected to see strong growth in the next few years. It will grow to $2.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to development of novel thrombolytic agents, increasing use of minimally invasive procedures, adoption of advanced imaging technologies, growth of personalized cardiology treatments, integration of ai and big data in cardiac care. Major trends in the forecast period include increasing adoption of percutaneous coronary intervention (pci) procedures, rising use of advanced cardiac biomarkers for early diagnosis, growing focus on minimally invasive cardiac treatments, expansion of telecardiology and remote patient monitoring, increasing awareness and prevention programs for acute mi.

Global Acute Myocardial Infarction Market Segmentation

1) By Type: ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI) 2) By Treatment Type: Thrombolytic Therapy, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG), Medications 3) By Diagnosis Method: Electrocardiogram, Cardiac Biomarkers, Echocardiography, Coronary Angiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan 4) By Route Of Administration: Oral Route, Intravenous (IV) Route, Subcutaneous Route, Transdermal Route, Sublingual Route 5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Specialty Cardiac Centers, Research Institutes Subsegments: 1) By ST-Elevation Myocardial Infarction (STEMI): Anterior ST-Elevation Myocardial Infarction (STEMI), Inferior ST-Elevation Myocardial Infarction (STEMI), Posterior ST-Elevation Myocardial Infarction (STEMI), Lateral ST-Elevation Myocardial Infarction (STEMI), Right Ventricular ST-Elevation Myocardial Infarction (STEMI), Extensive (Large) ST-Elevation Myocardial Infarction (STEMI) 2) By Non-ST-Elevation Myocardial Infarction (NSTEMI): Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI), Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI), Silent Non-ST-Elevation Myocardial Infarction (NSTEMI), Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)

What Is The Driver Of The Acute Myocardial Infarction Market?

The rising hypertension cases is expected to propel the growth of the acute myocardial infarction market going forward. Hypertension is a medical condition characterized by persistently high blood pressure, which increases the risk of heart disease, stroke, and other health complications. The hypertension cases is increasing due to the increasing prevalence of inactive lifestyles, caused by desk jobs, prolonged screen time, and minimal exercise. Hypertension contributes to acute myocardial infarction by damaging arteries, promoting plaque buildup, and increasing the risk of blood clots that can block coronary arteries. For instance, in September 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, in 2024, an estimated 1.4 billion adults aged 30–79 worldwide were living with hypertension, representing about one-third of the population in this age group. Therefore, the rising hypertension cases is driving the growth of the acute myocardial infarction industry.

Key Players In The Global Acute Myocardial Infarction Market

Major companies operating in the acute myocardial infarction market are Johnson & Johnson, F Hoffmann La Roche AG, Merck & Co Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Koninklijke Philips NV, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Pfizer Inc, Boehringer Ingelheim International GmbH, Amgen Inc

Global Acute Myocardial Infarction Market Trends and Insights

Major companies operating in the acute myocardial infarction market are focusing on obtaining regulatory approvals to expand their product portfolio, enhance treatment efficacy, and strengthen their market position. Regulatory approvals refer to official authorizations from health agencies such as the FDA and EMA, ensuring that drugs and medical devices meet safety, efficacy, and quality standards before market entry. For instance, in March 2025, Sungen Biomedical, a China-based biopharmaceutical company, received FDA Fast Track Designation for its monoclonal antibody drug, SGC001, the world's first developed for the emergency treatment of acute myocardial infarction (AMI). This designation recognizes SGC001’s potential to reduce cardiomyocyte apoptosis and improve blood flow in ischemic areas. With promising preclinical results indicating benefits in recovery and reduced mortality, Fast Track status enables expedited FDA communication, accelerating the approval process and ensuring quicker patient access to this innovative AMI therapy.

What Are Latest Mergers And Acquisitions In The Acute Myocardial Infarction Market?

In February 2023, BioCardia Inc., a US-based biotechnology company, extended its partnership with CellProthera to develop ProtheraCytes for the treatment of acute myocardial infarction. The partnership aims to utilize BioCardia’s Helix transendocardial biotherapeutic delivery system for CellProthera’s ongoing Phase I/IIb EXCELLENT study of its lead product candidate, ProtheraCytes. CellProthera is a France-based biotechnology company that focuses on regenerative therapy for acute myocardial infarction (AMI).

Regional Outlook

North America was the largest region in the acute myocardial infarction market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute Myocardial Infarction Market?

The acute myocardial infarction market consists of revenues earned by entities by providing services such as diagnostic testing, telemedicine consultations, remote patient monitoring, pharmaceutical treatments, and post-acute myocardial infarction (AMI) management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute myocardial infarction market also includes sales of pharmaceutical drugs, medical devices, diagnostic tools, wearable cardiac monitors, and telemedicine platforms for remote cardiac care. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acute Myocardial Infarction Market Report 2026?

The acute myocardial infarction market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acute myocardial infarction industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.